CGEM
Cullinan Therapeutics (CGEM)
$49
About Cullinan Therapeutics (CGEM)
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Details
Daily high
$14.28
Daily low
$13.12
Price at open
$14.08
52 Week High
$16.74
52 Week Low
$5.68
Market cap
816.5M
Dividend yield
0.00%
Volume
707,409
Avg. volume
885,910
P/E ratio
-3.62
Cullinan Therapeutics News
Details
Daily high
$14.28
Daily low
$13.12
Price at open
$14.08
52 Week High
$16.74
52 Week Low
$5.68
Market cap
816.5M
Dividend yield
0.00%
Volume
707,409
Avg. volume
885,910
P/E ratio
-3.62